Diabetes

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

Your daily dose of clinical news you may have missed.

The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.

In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.

Your daily dose of clinical news you may have missed.

CMHC 2022. Post-hoc analysis of the LIGHT-UP study found GS200 significantly reduced postprandial insulin secretion in adults with overweight and prediabetes.

CMHC. PCPs and cardiologists appeared to perform only half of items considered necessary for care of T2D patients in a new simulated patient study.

Your daily dose of clinical news from Patient Care Online.

CMHC 2022: A decrease in vitamin D levels is associated with increased cardiovascular risk in patients with type 2 diabetes, according to new study.

Analysis of national health data found that 16.5% of all adult insulin users skipped doses in the past year.

Early age at either type 1 or type 2 diabetes diagnosis was associated with earlier age a menopause, suggesting an impact of diabetes on reproductive health, authors say.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

Weight loss of at least 5% to 10% for persons with T2D is realistic and essential, says Nisa Maruthur, MD, MHS, coauthor of the new ADA/EASD consensus report.

Nisa Maruthur, MD, MHS, a primary care physician and consensus report coauthor, discusses elements of the most effective care for patients with type 2 diabetes (T2D).

Dr Maruthur, a PCP and coauthor for the new ADA/EASD consensus report on T2D, says that's why this report includes the "tips on implementation" sections.

Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.

As long as the role of social determinants of health in T2D is not prioritized, care for these patients will remain poor and outcomes will not improve, says consensus report author.

When modeled as first-line therapy vs metformin, treatment benefit was significantly outweighed by cost for both classes.

Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.

A T2D diagnosis in adults aged 50 to 59 years vs 60 to 69 years or ≥70 years was linked to significantly increased risk for cardio- and cerebrovascular disease and all-cause mortality.

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

Multimorbidity was associated with a 63% increased risk for dementia among adults older than age 60 years followed for up to 15 years.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.

Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.